U.S. pharmaceutical giant Pfizer has agreed to a license-sharing deal that would allow its experimental COVID-19 drug to be manufactured more widely around the globe.
It’s an agreement that the company says could give more than half of the world’s population access to the treatment, even as Pfizer rebuffs calls to grant poorer countries access to its COVID-19 vaccine formula.
The company said earlier this month that the drug, a pill regimen called paxlovid, reduced the risk of COVID-19 hospitalization or death by 89% when administered within three days of the onset of symptoms. It has not yet received regulatory approval in the U.S., but Pfizer said it plans to seek authorization from the Food and Drug Administration as soon as possible.
“This license is so important because, if authorized or approved, this oral drug is particularly well-suited for low- and middle-income countries and could play a critical role in saving lives, contributing to global efforts to fight the current pandemic,” said Charles Gore, executive director of Medicines Patent Pool, the nonprofit group that reached the agreement with Pfizer.
MPP is backed by the United Nations and has a mandate to facilitate global access to life-saving medicines. Pfizer is the second drug manufacturer to reach an agreement with the group, which can grant sub-licenses to other manufacturers to produce generic versions of the pill.
U.S. pharmaceutical giant Merck announced last month that it had agreed to share the license for its own COVID-19 antiviral pill, molnupiravir, that it developed with Ridgeback Biotherapeutics.
Read More
The fact that a second COVID-19 drug could see wider use with an MPP agreement is “very good news,” said Ellen ‘t Hoen, director of the research group Medicines Law & Policy.
“This is setting the precedent that if you have a COVID-19 countermeasure, you license for wider use,” said Ms. ‘t Hoen, who is also a member of an MPP expert advisory group.
Since the pandemic erupted last year, researchers worldwide have raced to develop a pill to treat COVID-19 that can be taken at home easily to ease symptoms, speed recovery and keep people out of the hospital. At the moment, most COVID-19 treatments must be delivered intravenously or by injection.
Pfizer and MPP said in a joint statement that the deal would allow manufacturers to supply countries comprising some 53% of the world’s population — and that the company would offer tiered pricing based on a country’s ability to pay. Lower-income countries would pay a not-for-profit price.
Pfizer will also forgo royalties in low-income countries and waive them in others, so long as COVID-19 remains an international public health emergency, the statement said.
“It’s quite significant that we will be able to provide access to a drug that appears to be effective and has just been developed, to more than 4 billion people,” said Esteban Burrone, head of policy at the Medicines Patent Pool.
He estimated that other drugmakers would be able to start producing the pill within months but acknowledged the agreement wouldn’t please everyone.
“We try to strike a very delicate balance between the interests of the [company], the sustainability required by generic producers and, most importantly, the public health needs in lower- and middle-income countries,” Mr. Burrone said.
The deal excludes some large countries that have suffered devastating coronavirus outbreaks. For example, while a Brazilian drug company could get a license to make the pill for export to other countries, the medicine could not be made generically for use in Brazil.
Still, health officials said the fact that the deal was struck even before Pfizer’s pill has been authorized anywhere, could help to end the pandemic quicker.
“Oral antiviral treatments can play a vital role in reducing the severity of COVID-19 infections, decreasing the strain on our health care systems and saving lives,” said Albert Bourla, Pfizer’s chairman and CEO.
“We must work to ensure that all people — regardless of where they live or their circumstances — have access to these breakthroughs, and we are pleased to be able to work with MPP to further our commitment to equity,” he said in a statement.
But while the COVID-19 pills appear to mark a significant step toward managing the pandemic, experts say that the anti-virals are not a magic bullet — and that Pfizer and other vaccine producers should license their intellectual property and know-how regarding the shots to the patent pool.
“After all, prevention is better than cure,” said Ms. ‘t Hoen.
Fewer than 1% of Pfizer’s COVID-19 shots have gone to poorer countries.
Doctors Without Borders said it was “disheartened” that the Pfizer deal does not make the drug available to the entire world, noting that the agreement announced Tuesday also excludes countries including China, Argentina and Thailand.
“The world knows by now that access to COVID-19 medical tools needs to be guaranteed for everyone, everywhere, if we really want to control this pandemic,” said Yuanqiong Hu, a senior legal policy adviser at Doctors Without Borders.
In some countries where access to testing is limited, experts say it could be difficult to diagnose patients with COVID-19 in time to administer Pfizer’s pill regimen effectively.
Mr. Bourla, the CEO, has been a vocal critic of those urging Pfizer to share its vaccine formula, which the company developed with the German firm BioNTech: He called the idea of sharing the vaccine information “nonsense” and “dangerous” at a forum last year.
Pfizer spokesman Kit Longley defended the company’s approach in a statement this week and raised concerns about the ability of organizations “without a proven track record” to manufacture high-quality vaccines.
“While we pursue our current strategy, we will continue to evaluate whether and where other options may be appropriate,” he said.
Paxlovid and molnupiravir are not designed to prevent infection, but, as pill-based drugs, they are easier to store and administer than vaccines. They also do not rely on the complicated messenger RNA technology that powers the Pfizer shot.
Both drugs have been studied for use specifically in high-risk individuals. And Britain recently authorized molnupiravir only for patients who are 60 or older or have at least one underlying condition that puts them at risk of developing severe illness.
The Associated Press contributed.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.